DK1034000T3 - Fremgangsmåde til fremstilling af vacciner til forebyggelse af de patogene virkninger relateret til en HIV-retrovirusinfektion - Google Patents

Fremgangsmåde til fremstilling af vacciner til forebyggelse af de patogene virkninger relateret til en HIV-retrovirusinfektion

Info

Publication number
DK1034000T3
DK1034000T3 DK98955673T DK98955673T DK1034000T3 DK 1034000 T3 DK1034000 T3 DK 1034000T3 DK 98955673 T DK98955673 T DK 98955673T DK 98955673 T DK98955673 T DK 98955673T DK 1034000 T3 DK1034000 T3 DK 1034000T3
Authority
DK
Denmark
Prior art keywords
prevent
effects related
pathogenic effects
retrovirus infection
preparing vaccines
Prior art date
Application number
DK98955673T
Other languages
English (en)
Inventor
Pierre-Francois Serres
Christophe Geourjon
Gilbert Deleage
Christophe Combet
Original Assignee
Mymetics Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Mymetics Sa filed Critical Mymetics Sa
Application granted granted Critical
Publication of DK1034000T3 publication Critical patent/DK1034000T3/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/21—Retroviridae, e.g. equine infectious anemia virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/08—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from viruses
    • C07K16/10—RNA viruses
    • C07K16/112—Retroviridae (F), e.g. leukemia viruses
    • C07K16/114—Lentivirus (G), e.g. human immunodeficiency virus [HIV], feline immunodeficiency virus [FIV] or simian immunodeficiency virus [SIV]
    • C07K16/1145—Env proteins, e.g. gp41, gp110/120, gp160, V3, principal neutralising domain [PND] or CD4-binding site
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/244—Interleukins [IL]
    • C07K16/246—IL-2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/15011—Lentivirus, not HIV, e.g. FIV, SIV
    • C12N2740/15022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16111—Human Immunodeficiency Virus, HIV concerning HIV env
    • C12N2740/16122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16111—Human Immunodeficiency Virus, HIV concerning HIV env
    • C12N2740/16134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Communicable Diseases (AREA)
  • Microbiology (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • AIDS & HIV (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
DK98955673T 1997-11-17 1998-11-17 Fremgangsmåde til fremstilling af vacciner til forebyggelse af de patogene virkninger relateret til en HIV-retrovirusinfektion DK1034000T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR9714387A FR2771011B1 (fr) 1997-11-17 1997-11-17 Obtention de vaccins destines a prevenir les effets pathogenes associes a une infection retrovirale
PCT/FR1998/002447 WO1999025377A1 (fr) 1997-11-17 1998-11-17 Obtention de vaccins destines a prevenir les effets pathogenes associes a une infection retrovirale

Publications (1)

Publication Number Publication Date
DK1034000T3 true DK1034000T3 (da) 2007-06-04

Family

ID=9513450

Family Applications (1)

Application Number Title Priority Date Filing Date
DK98955673T DK1034000T3 (da) 1997-11-17 1998-11-17 Fremgangsmåde til fremstilling af vacciner til forebyggelse af de patogene virkninger relateret til en HIV-retrovirusinfektion

Country Status (19)

Country Link
US (3) US6455265B1 (da)
EP (1) EP1034000B1 (da)
JP (1) JP4837823B2 (da)
KR (1) KR20010032210A (da)
CN (1) CN1281371A (da)
AP (1) AP2000001841A0 (da)
AT (1) ATE353017T1 (da)
AU (1) AU1243499A (da)
BR (1) BR9814204A (da)
CA (1) CA2309676C (da)
DE (1) DE69837012T2 (da)
DK (1) DK1034000T3 (da)
EA (1) EA200000528A1 (da)
ES (1) ES2281938T3 (da)
FR (1) FR2771011B1 (da)
IL (2) IL136163A0 (da)
OA (1) OA11522A (da)
PT (1) PT1034000E (da)
WO (1) WO1999025377A1 (da)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2771011B1 (fr) * 1997-11-17 2000-01-28 Hippocampe Obtention de vaccins destines a prevenir les effets pathogenes associes a une infection retrovirale
CN1396178A (zh) * 2002-06-17 2003-02-12 成都阳辉生物科技有限责任公司 抗乙肝病毒等包膜病毒感染的工程多肽及其制备方法
EP1466924B9 (en) * 2003-04-11 2013-06-19 Institut Pasteur Synthetic peptide vaccines for HIV: the CBD epitope as an effective immunogen to elicit broadly neutralizing antibodies against HIV
CN1860130B (zh) 2003-07-30 2012-05-30 迈梅蒂克斯公司 新的可溶且稳定的三聚体形式的gp41多肽
DE602004021829D1 (de) * 2003-09-11 2009-08-13 Idexx Lab Inc Verfahren zum nachweis des felinen immunschwächevirus
AU2005267607B8 (en) * 2003-09-11 2009-07-16 Idexx Laboratories, Inc. Method and device for detecting feline immunodeficiency virus
AU2004304348B2 (en) * 2003-12-18 2009-02-26 Idexx Laboratories, Inc. Method and device for detecting feline immunodeficiency virus
ATE504834T1 (de) * 2004-02-19 2011-04-15 Idexx Lab Inc Verfahren und vorrichtung zum nachweis von katzen-immunschwächevirus
AU2005229411B2 (en) * 2004-03-30 2010-11-18 Centre National De La Recherche Scientifique Polypeptide sequence involved in the modulation of the immunosuppressive effect of viral proteins
CA2576930C (en) * 2004-06-30 2011-06-07 Idexx Laboratories, Inc. Method and device for detecting feline immunodeficiency virus (fiv) comprising the use of peptides derived from the v3 region of the fiv env protein
JP4662988B2 (ja) * 2004-06-30 2011-03-30 アイデックス ラボラトリーズ インコーポレイテッド ネコ免疫不全ウイルスを検出するための方法および装置
US7291338B2 (en) * 2005-03-09 2007-11-06 Idexx Laboratories, Inc. Method and device for detecting feline immunodeficiency virus
JP5020941B2 (ja) * 2005-05-02 2012-09-05 マイメティクス コーポレーション Ｈｉｖに対して中和活性を有するがｉｌ２には中和活性を有さない抗体又はその断片
TWI343180B (en) * 2005-07-01 2011-06-01 Ind Tech Res Inst The acoustic wave sensing-device integrated with micro channels
WO2007099387A1 (en) * 2006-03-03 2007-09-07 Mymetics Corporation Virosome-like vesicles comprising gp41-derived antigens
CN1869704B (zh) * 2006-06-14 2010-06-30 厦门大学 快速鉴定与病原菌互作的宿主蛋白的方法
US20110195089A1 (en) * 2008-10-08 2011-08-11 The Adminstrators Of The Tulane Educational Fund Compositions, methods, and kits for enhancing the immunogenicity of pathogenic antigens
AP3402A (en) 2009-02-06 2015-08-31 Mymetics Corp Splitting GP41
KR101756202B1 (ko) 2009-02-06 2017-07-10 마이메틱스 코포레이션 신규한 ｇｐ41 항원
US20120148594A1 (en) * 2009-08-21 2012-06-14 Dana-Farber Cancer Institute, Inc. Mimotopes of hiv and uses thereof
WO2011123781A1 (en) 2010-04-02 2011-10-06 Idexx Laboratories, Inc. Detection of feline immunodeficiency virus
ES2667425T3 (es) 2011-06-10 2018-05-10 Oregon Health & Science University Glucoproteínas y vectores recombinantes de CMV
EP2890392B1 (en) 2012-08-30 2019-04-17 Merial, Inc. Expression of chimeric ksac protein and method of producing soluble proteins by high pressure
US20220065857A1 (en) * 2018-12-12 2022-03-03 The Johns Hopkins University Hiv serosignatures for cross-sectional incidence estimation
WO2021185851A1 (en) 2020-03-17 2021-09-23 INSERM (Institut National de la Santé et de la Recherche Médicale) Vaccine compositions for hiv prevention and treatment
CN111701016A (zh) * 2020-06-28 2020-09-25 张全志 逆转录病毒原病毒序列在逆转录病毒疫苗设计中的应用
CN118515733B (zh) * 2023-02-20 2025-11-18 菲鹏生物股份有限公司 Hiv蛋白及其在检测hiv抗体中的应用
CN118561966B (zh) * 2024-05-20 2025-07-11 浙江大学 人内源性逆转录病毒包膜蛋白突变体、截短体及其用途

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1993001304A1 (en) * 1991-07-10 1993-01-21 Synbiotics Corporation Synthetic peptides related to fiv-env proteins
KR100358209B1 (ko) * 1992-07-20 2003-01-24 듀크 유니버시티 Hiv복제를저해하는조성물
GB9219936D0 (en) * 1992-09-21 1992-11-04 Pitman Moore Inc Vaccines
US6017536A (en) * 1993-06-07 2000-01-25 Trimeris, Inc. Simian immunodeficiency virus peptides with antifusogenic and antiviral activities
US6479055B1 (en) * 1993-06-07 2002-11-12 Trimeris, Inc. Methods for inhibition of membrane fusion-associated events, including respiratory syncytial virus transmission
FR2771011B1 (fr) * 1997-11-17 2000-01-28 Hippocampe Obtention de vaccins destines a prevenir les effets pathogenes associes a une infection retrovirale

Also Published As

Publication number Publication date
PT1034000E (pt) 2007-05-31
CA2309676C (fr) 2012-08-07
EP1034000A1 (fr) 2000-09-13
AP2000001841A0 (en) 2000-06-30
JP2001524456A (ja) 2001-12-04
EP1034000B1 (fr) 2007-01-31
CA2309676A1 (fr) 1999-05-27
FR2771011B1 (fr) 2000-01-28
US6455265B1 (en) 2002-09-24
US7253270B2 (en) 2007-08-07
ES2281938T3 (es) 2007-10-01
FR2771011A1 (fr) 1999-05-21
EA200000528A1 (ru) 2001-02-26
US20080003229A1 (en) 2008-01-03
DE69837012D1 (de) 2007-03-22
US20050048478A9 (en) 2005-03-03
CN1281371A (zh) 2001-01-24
WO1999025377A1 (fr) 1999-05-27
US20040014046A1 (en) 2004-01-22
IL136163A (en) 2007-07-04
DE69837012T2 (de) 2007-11-29
AU1243499A (en) 1999-06-07
KR20010032210A (ko) 2001-04-16
OA11522A (fr) 2004-02-09
ATE353017T1 (de) 2007-02-15
IL136163A0 (en) 2001-05-20
US7829683B2 (en) 2010-11-09
BR9814204A (pt) 2000-10-03
JP4837823B2 (ja) 2011-12-14

Similar Documents

Publication Publication Date Title
DK1032566T5 (da) Fremgangsmåde til fremstilling af citalopram
DK1173431T4 (da) Fremgangsmåde til fremstilling af citalopram
DK1105382T3 (da) Fremgangsmåde til fremstilling af citalopram
DK1159274T3 (da) Fremgangsmåde til fremstilling af citalopram
DK1123284T3 (da) Fremgangsmåde til fremstilling af citalopram
ATE197406T1 (de) Influenza vaccine
ATE209045T1 (de) Hepatitis b impfstoff
DK1038008T3 (da) Fremgangsmåde til fremstilling af EGIII-lignende enzymer
DE69837012D1 (de) Herstellung von impstoffen zür vorbeugung von pathogenen zuständen einer hiv retroviraler infektion
DK1309581T3 (da) Fremgangsmåde til fremstilling af citalopram
DK1140886T3 (da) Fremgangsmåde til fremstilling af 5-cyanophtalid
DK0905254T3 (da) Fremgangsmåde til fremstilling af en lavemolekylær
DK0996642T3 (da) Fremgangsmåde til fremstilling af heparin
DK0538303T3 (da) Fremgangsmåde til fremstilling af cycliske sulfater
DK0875579T3 (da) Fremstilling af L(+)-laktat
DK0912603T3 (da) Fremgangsmåde til fremstilling af visse azacyclohexapeptider
DK1296970T3 (da) Fremgangsmåde til fremstilling af citalopram
DK1228056T3 (da) Fremgangsmåde til fremstilling af citalopram
DK1203000T3 (da) Fremgangsmåde til fremstilling af phosphonomethylglycin
DK0871616T3 (da) Fremgangsmåde til fremstilling af lægemidler mod malaria
DK1240173T3 (da) Fremgangsmåde til fremstilling af N-phosphonomethylglycin
DK1012152T3 (da) Fremgangsmåde til fremstilling af oxazaphosphorin-2-aminer
DK1105498T3 (da) HIV vaccine
DK425989D0 (da) Hydrolyse af phospholipider
DK1238094T3 (da) Fremgangsmåde til fremstilling af optisk aktive cyanhyhydriner under anvendelse af R-oxynitrilase